Besim Ogretmen was named assistant vice president for research in the Office of the Vice President for Research at the Medical University of South Carolina.
Florida Cancer Specialists & Research Institute, LLC has been awarded two grants by the Florida Cancer Innovation Fund.
The Hebrew University of Jerusalem and Georgetown University have established a joint initiative on cancer to amplify innovation, discovery and action to end the disease.
Roger Lo, a professor of medicine, dermatology and molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, has received a $1 million “All-Star” grant from the V Foundation to develop strategies to prevent relapse in patients with advanced melanoma by targeting drug resistance before it takes root.
LeanTaaS Inc. has conducted a national survey of nearly 200 nursing and operational leaders from community hospitals, academic medical centers, and private oncology practices.
A recent study from cancer researchers at the University of Alabama at Birmingham and Georgia State University has identified a new therapeutic target in quadruple-negative breast cancer, or QNBC, one of the deadliest and most aggressive treatment-resistant forms of breast cancer.
Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options.
New research shows that a rare group of pancreatic cancer patients responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type.
A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks the cancer’s ability to invade other tissue, a new study shows.
FDA has approved Zegfrovy (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
